Search Within

Jacqueline Bromberg

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (9)
Groups
  1. Biostatistics Service (19)
  2. Breast Medicine Service (19)
  3. Department of Medicine (19)
  4. Epidemiology and Biostatistics (19)
  5. GSK Faculty (19)
  6. Solid Tumor Oncology Division (19)

More Groups

People
  1. Shanu Modi (12)
  2. Sujata Patil (11)
  3. Tiffany Traina (10)
  4. Larry Norton (9)
  5. Ayca Gucalp (8)
  6. Chau Dang (8)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (3)
  4. 2021 (1)
  5. 2020 (2)
  6. 2019 (1)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer Research (3)
  3. Clinical Breast Cancer (2)
  4. Clinical Cancer Research (2)
  5. International Journal of Radiation Oncology, Biology, Physics (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (5)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (4)
  4. Oxford University Press (2)
  5. Nature Publishing Group (1)
  6. Society of Nuclear Medicine (1)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Journal Article

    Mai, N.; dos Anjos, C. H.; Razavi, P.; Safonov, A.; Patil, S.; Chen, Y.; Drago, J. Z.; Modi, S.; Bromberg, J. F.; Dang, C. T.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • First-in-human evaluation of site-specifically labeled (89)Zr-pertuzumab in patients with HER2-positive breast cancer
    Journal Article

    Yeh, R.; O'Donoghue, J. A.; Jayaprakasam, V. S.; Mauguen, A.; Min, R.; Park, S.; Brockway, J. P.; Bromberg, J. F.; Zhi, W. I.; Robson, M. E.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: A randomized trial
    Journal Article

    Scott, J. M.; Lee, J.; Herndon, J. E.; Michalski, M. G.; Lee, C. P.; O'Brien, K. A.; Sasso, J. P.; Yu, A. F.; Rowed, K. A.; Bromberg, J. F.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study
    Journal Article

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer
    Meeting Abstract

    Gucalp, A.; Boyle, L. A.; Alano, T.; Arumov, A.; Gounder, M. M.; Patil, S.; Feigin, K.; Edelweiss, M.; D'Andrea, G.; Bromberg, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save